Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R: Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009, 18 (3): 808-15.
Peng P, Gong YM, Bao PP, Ke JZ, Xiang YM, Zhang ML, Zheng Y: [Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012, 33 (10): 1056-9.
Delongchamps NB, Singh A, Haas GP: The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006, 13 (3): 158-68.
Li J, German R, King J, Joseph D, Thompson T, Wu XC, Ajani U, Tai E: Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol. 2012, 36 (2): 122-7.
Yu XQ, Luo Q, Smith DP, Clements MS, O'Connell DL: Prostate cancer prevalence in New South Wales Australia: a population-based study. Cancer Epidemiol. 2015, 39 (1): 29-36.
Ondrusova M, Mrozova L, Ondrus D, Mrinakova B: Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012. Neoplasma. 2013, 60 (4): 446-51.
['Atsaceišona nu: medicinys']
['Itei interneta vītne ir dūmuota tikai izgleiteibys i informacejis īmeslim, i tei nateik skaiteita par medicinys pīduovuojumu voi profesionalu pakolpuojumu.']
['Pīduovuotū informaceju nadreikst lītuot, kab diagnosticātu voi izuorstātu kaidu slimeibu, i tim, kas meklej personeigu mediciniskū padūmu, juosazynoj ar licencātu uorstu.']
['Juopīzeist, ka neironu teikls, kas generej atbiļdis iz vaicuojumim, ir eipaši napareizs, kod runoj par skaitliskū saturu, par pīmāru, par konkretu slimeibu diagnozātūs cylvāku skaitu.']
['Vysod meklejit padumu nu sova uorsta voi cyta kvalificāta uorsta, kab saprostu jiusu slimeibu. Nikod naatsakuortojit profesionalū uorsta padumu voi aizkavejit tū mekliešonu deļtuo, ka esat koč kū izlasiejs itamā interneta vītnē. Ka jiusim ruodīs, ka jiusim var byut uorsteibys uorkuortys situaceja, zvaniet 911 voi īīt tyvuokajā uorstnīceibys centrā.']
['Atsaceišona: autortiesības']
['1998. goda Digitaluo tyukstūšgadis autoru tīseibu lykums, 17 U.S.C. § 512 (DMCA) nūdrūsynoj tīseibu aizstuoviešonu autoru tīseibu turātuojim, kuri skaita, ka materialā, kas pasaruoda iz škārsteikla, ir puorkuoptys jūs tīseibys saskaņā ar ASV autoru tīseibu lykumim. ']
['Ka jius iz lobu tycat, ka kaids saturs voi materials, kas ir pīejams saisteibā ar myusu sātom voi pakolpuojumim, puorkuop jiusu autortiesības, jius (voi jiusu aģents) jiusim var syuteit paziņuojumu, kurā lyugts svīgt itū saturu voi materialu voi bloķēt pīeju tam.']
['Paziņuojumi ir juonūsyuta e-postā (vērtīs sadaļu "Kontakti" e-posta adresei).']
['DMCA prasej, kab jiusu paziņuojumā par īspiejamu autortiesību puorkuopumu byutu īkļauta itei informaceja: (1) ar autortiesībām aizsorguotuo dorba aproksts, kas ir īspiejamuos puorkuopuma objekts; (2) īspiejamuos puorkuopuma satura aproksts i informaceja, kas ir pīteikama, kab ļautu mums atrast saturu; (3) jiusu kontaktinformaceja, tymā skaitā adrese, telefona numurs i e-posta adrese; (4) apstyprynuojums, ka jius asat puorlīcynuots, ka saturs tai, kai ir ībyldts, nav atļauts ar autortiesību eipašnīka voi juo aģenta voi kaida lykuma atbolstu; ']
['5. aplīcynuojumu, ka jiusu informaceja ir pareiza i ka jiusim ir tīseibys izmontuot autortīseibys, kuruos ir nūlīgts lītuot;']
['i 6) fizisks voi elektronisks autortīseibu turātuoja voi personas, kas ir pilnvarota dorbuotīs autortīseibu turātuoja vuordā, paraksts.']
['Lyudzu, syutiet mums e-postu ar sevkuru vaicuojumu/ieteikumu.']
How common is prostate cancer?
Prostate cancer is one of the most common types of cancer in men, particularly in older men.
According to the American Cancer Society, prostate cancer is the second most common cancer in American men, behind skin cancer.
In the United States, about 1 in 9 men will be diagnosed with prostate cancer during their lifetime.
In 2021, it is estimated that there will be about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer.
However, it is important to note that prostate cancer is highly treatable, and the survival rate is high when it is detected early.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
